Russian billionaire nabs Veropharm for $155M; Boehringer gears up for first cancer-drug launch;

@FiercePharma: Trending on our website: Top 20 orphan drugs by 2018. Special Report | Follow @FiercePharma

@CarlyHFierce: China's Simcere going private thanks to $495M buyout by chairman. ICYMI yesterday | Follow @CarlyHFierce

> Russian billionaire Roman Avdeev bought Veropharm, the generics unit of Pharmacy Chain 36.6 that's been up for sale, for 5 billion rubles ($151 million). Release | Report

> Boehringer Ingelheim is prepping for the U.S. launch of its first cancer drug, Gilotrif, approved by FDA in July. Report

> Japan's Takeda Pharmaceutical added a CFO position to its executive roster and named François-Xavier Roger, lately CFO of Millicom International, to take on the role. Report

> The FDA says it will take three months longer to review a new use for Auxilium Pharmaceuticals' Xiaflex in Peyronie's disease. Report

> Sanofi ($SNY) successfully priced a €1 billion notes offering, due 2020, at an interest rate of 1.875%. Release (PDF)

> Merck ($MRK) plans a contraception awareness campaign in the U.K. to talk up long-term birth-control options. Report

Medical Device News

@FierceMedDev: Sign up to receive our new publication FierceDiagnostics in your inbox each Wednesday. Sign up here | Follow @FierceMedDev

@DamianFierce: St. Jude won a CE mark for its next-gen renal denervation device. News | Follow @DamianFierce

@MarkHFierce: There's a new brain cancer MRI Dx approach, and Harvard Medical School is partially behind it. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: Chip lined with human cells tests cancer drug delivery with minimal cost. FierceDrugDelivery article | Follow @MichaelGFierce

> Biotronik boosts MRI-safe options for pacemaker tech. Story

> LipoScience back to drawing board after FDA rebuff. Report

> HeartWare expands heart pump trial for destination therapy. More

Biotech News

@FierceBiotech: Popular yesterday: Gilead's sofosbuvir cures some of the toughest hepatitis C cases. Article | Follow @FierceBiotech

@JohnCFierce: Strange story: Low-profile Epirus lays claim to a PhIII success for Remicade biosimilar--backed by TPG, 5AM. News | Follow @JohnCFierce

@RyanMFierce: GoogleVentures bets on oral biologics from startup Rani Therapeutics. Report | Follow @RyanMFierce

@EmilyMFierce: Worm genome reveals possible drug targets. Item from FierceBiotech Research | Follow @EmilyMFierce

> Human 'mini brains' grown in lab could aid drug discovery. Article

> J&J hands over $75M payout as FDA countdown begins for ibrutinib. More

Vaccines News

> Novartis begins shipping flu vaccines ahead of crucial season. Article

> Analysis finds most vaccines safe during breastfeeding. Report

> International Vaccine Institute inks Indian alliances. Item

> Herd immunity from GSK, Merck vaccines cutting hospitalizations. Story

> Low vaccination rate at megachurch linked to measles outbreak. Report

Pharma Manufacturing News

@EricPFierce: India's GRAF building nutraceutical plant. It sees the category as source of future revenue growth. Article | Follow @EricPFierce

> Injectable drugs to drive CMO growth. Story

> Fast-growing ICIG adds peptide manufacturer. Article

> Novartis OTC unit has another foul-up. Report

> DOJ files suit against plant with persistent issues. More

And Finally... China's ambitious healthcare reform will be complicated by its rapidly aging population. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.